| abstract |
A novel delivery method and system for administering a neuroprotective agent to a patient to treat an ophthalmic condition. In vivo, a sirtuin activator; and an sirtuin activator that releases the sirtuin activator at a rate effective to provide sustained release of an amount of the sirtuin activator from the implant for at least about one week after placement of the implant in the eye An intraocular implant comprising a degradable polymer matrix. Sirtuin activators consist of resveratrol, butein, piceatannol, isoliquiritigenin, fisetin, luteolin, analogs thereof and derivatives thereof such as 3,6,3 ′, 4′-tetrahydroxyflavone Select from group. The biodegradable polymer matrix is selected from the group consisting of poly (lactide-co-glycolide) polymer (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polyester, and the like, and derivatives and combinations thereof. [Selection] Figure 1 |